These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798 [TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. Cervera-Carrascon V; Havunen R; Hemminki A Expert Opin Biol Ther; 2019 May; 19(5):443-455. PubMed ID: 30905206 [TBL] [Abstract][Full Text] [Related]
7. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768 [TBL] [Abstract][Full Text] [Related]
8. Mining the adenovirus "virome" for systemic oncolytics. Barry MA; Weaver EA; Chen CY Curr Pharm Biotechnol; 2012 Jul; 13(9):1804-8. PubMed ID: 21740366 [TBL] [Abstract][Full Text] [Related]
9. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis. Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865 [TBL] [Abstract][Full Text] [Related]
10. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Strauss R; Lieber A Curr Opin Mol Ther; 2009 Oct; 11(5):513-22. PubMed ID: 19806499 [TBL] [Abstract][Full Text] [Related]
11. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824 [TBL] [Abstract][Full Text] [Related]
12. Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses. Lu SC; Barry MA Expert Opin Biol Ther; 2022 Nov; 22(11):1359-1378. PubMed ID: 36300528 [TBL] [Abstract][Full Text] [Related]
13. Construction of targeted and armed oncolytic adenoviruses. Doronin K; Shayakhmetov DM Methods Mol Biol; 2012; 797():35-52. PubMed ID: 21948467 [TBL] [Abstract][Full Text] [Related]
15. Modification of oncolytic adenovirus and its application in cancer therapy. Liang Y; He J; Zhao Y Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481 [TBL] [Abstract][Full Text] [Related]
16. Tumor Targeting of Oncolytic Adenoviruses Using Bispecific Adapter Proteins. Niemann J; Kühnel F Methods Mol Biol; 2020; 2058():31-49. PubMed ID: 31486030 [TBL] [Abstract][Full Text] [Related]
17. Chapter four--Design of improved oncolytic adenoviruses. Alemany R Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243 [TBL] [Abstract][Full Text] [Related]
18. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Zhang L; Hedjran F; Larson C; Perez GL; Reid T Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035 [TBL] [Abstract][Full Text] [Related]
19. Evolution of oncolytic adenovirus for cancer treatment. Choi JW; Lee JS; Kim SW; Yun CO Adv Drug Deliv Rev; 2012 Jun; 64(8):720-9. PubMed ID: 22212901 [TBL] [Abstract][Full Text] [Related]
20. [Advances in research on oncolytic adenoviruses in tumor therapy]. Zhou XL; Tang WR Bing Du Xue Bao; 2014 May; 30(3):318-24. PubMed ID: 25118389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]